Title:
NOVEL ANTIBODY FOR PREVENTION OR TREATMENT OF FIBROTIC DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/008858
Kind Code:
A1
Abstract:
The present invention relates to a method for prevention or treatment of fibrotic disease, wherein an antibody binding specifically to thrombospondin-2 (TSP-2) protein involved in fibrosis is used for predicting the onset of fibrotic disease or for inhibiting the activity of the corresponding protein. The present invention presents TSP-2 as a new diagnostic and therapeutic target for idiopathic pulmonary fibrosis, for which there have been no effective treatment methods because a clear pathogenesis is not known, and provides an effective antibody that can be used for effective diagnosis, prevention, or treatment of idiopathic pulmonary fibrosis. In addition, the present invention can be advantageously used to effectively block fibrosis in various tissues by ultimately providing a fundamental inhibition method for pathological fibrosis mechanisms.
Inventors:
YOON HOGEUN (KR)
PARK SOO-YEON (KR)
PARK SOO-YEON (KR)
Application Number:
PCT/KR2022/010881
Publication Date:
February 02, 2023
Filing Date:
July 25, 2022
Export Citation:
Assignee:
UNIV YONSEI IACF (KR)
International Classes:
C07K16/18; A61K39/00; A61P11/00; A61P43/00
Foreign References:
| KR20010105403A | 2001-11-28 | |||
| US11066462B2 | 2021-07-20 |
Other References:
HOFFMANN JULIA, WILHELM JOCHEN, MARSH LEIGH M., GHANIM BAHIL, KLEPETKO WALTER, KOVACS GABOR, OLSCHEWSKI HORST, OLSCHEWSKI ANDREA, : "Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN THORACIC SOCIETY, US, vol. 190, no. 1, 1 July 2014 (2014-07-01), US , pages 98 - 111, XP093023536, ISSN: 1073-449X, DOI: 10.1164/rccm.201401-0037OC
REINECKE HANS, ROBEY THOMAS E., MIGNONE JOHN L., MUSKHELI VERONICA, BORNSTEIN PAUL, MURRY CHARLES E.: "Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts", CARDIOVASCULAR PATHOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 1, 1 January 2013 (2013-01-01), AMSTERDAM, NL , pages 91 - 95, XP093029777, ISSN: 1054-8807, DOI: 10.1016/j.carpath.2012.03.005
CUI YU, JI JIE, HOU JIWEI, TAN YI, HAN XIAODONG: "Identification of Key Candidate Genes Involved in the Progression of Idiopathic Pulmonary Fibrosis", MOLECULES, vol. 26, no. 4, 1 January 2021 (2021-01-01), pages 1123, XP093029778, DOI: 10.3390/molecules26041123
JIANG YI-MING, YU DAN-LU, HOU GUO-XIN, JIANG JIA-LU, ZHOU QIANG, XU XIAO-FANG: "Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer", CELL DEATH AND DISEASE, vol. 39, no. 7, 31 July 2019 (2019-07-31), pages 20190476, XP093029780, ISSN: 0144-8463, DOI: 10.1042/BSR20190476
REINECKE HANS, ROBEY THOMAS E., MIGNONE JOHN L., MUSKHELI VERONICA, BORNSTEIN PAUL, MURRY CHARLES E.: "Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts", CARDIOVASCULAR PATHOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 1, 1 January 2013 (2013-01-01), AMSTERDAM, NL , pages 91 - 95, XP093029777, ISSN: 1054-8807, DOI: 10.1016/j.carpath.2012.03.005
CUI YU, JI JIE, HOU JIWEI, TAN YI, HAN XIAODONG: "Identification of Key Candidate Genes Involved in the Progression of Idiopathic Pulmonary Fibrosis", MOLECULES, vol. 26, no. 4, 1 January 2021 (2021-01-01), pages 1123, XP093029778, DOI: 10.3390/molecules26041123
JIANG YI-MING, YU DAN-LU, HOU GUO-XIN, JIANG JIA-LU, ZHOU QIANG, XU XIAO-FANG: "Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer", CELL DEATH AND DISEASE, vol. 39, no. 7, 31 July 2019 (2019-07-31), pages 20190476, XP093029780, ISSN: 0144-8463, DOI: 10.1042/BSR20190476
Attorney, Agent or Firm:
PADO IP LAW PLLC (KR)
Download PDF: